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Introduction: Few validated prognostic factors are available for
survival in patients with lung cancer. [18F]-fluoro-2-deoxy-D-glu-
cose positron emission tomography has been shown to be of addi-
tional value to conventional imaging for staging lung cancer. The
prognostic value of this lung tumor metabolic activity was studied in
a first systematic review of studies published until 2006.
Methods: As further studies have appeared since 2006, this report
has as objective to confirm and to estimate with less variability the
prognostic value of primary tumor standardized uptake value (SUV)
measured with [18F]-fluoro-2-deoxy-D-glucose positron emission
tomography on the basis of an updated search of eligible studies.
Results: Ten additional studies were eligible for the updated review
and eight of them provided, in the publication, data allowing
survival results aggregation. All together, 21 studies were analyzed.
Comparing patients with low and high SUV, using preferentially the
median SUV value of each study as threshold, we obtained a poor
prognostic value for high SUV compared with low SUV with an
overall combined hazard ratio of 2.08, significantly different from
one with a 95% confidence interval ranging from 1.69 to 2.56. No
interaction between older and newer studies was detectable (P 
0.60) as well as between studies having selected non metastatic
patients or studies without selection criterion related to stage (P 
0.46).
Conclusions: We confirmed the results of our previous review
showing that SUV is potentially a very interesting factor for pre-
dicting patient outcome. We believe that a meta-analysis based on
individual patient data would be of great value as allowing to assess
the independent prognostic value, to take into account some factors
responsible for heterogeneity between studies (SUV assessment
method, disease stage, and histology), and to update survival data.
We are planning to conduct such a meta-analysis on behalf of the
International Association for the Study of Lung Cancer Staging
Project.
Key Words: Lung cancer, 18FDG-PET scan, Prognostic factor,
Survival, Systematic review.
(J Thorac Oncol. 2010;5: 612–619)
Up to now, there are, for lung cancer, very few validatedprognostic factors in use in clinical practice. Although
many clinical, pathologic, routine laboratory markers, molec-
ular biologic markers, and gene signatures have been sug-
gested as possible univariate or independent prognostic fac-
tors, only two characteristics are definitely established as
independently associated with prognosis: performance status
and disease stage.1 This has been recently confirmed by the
International Association for the Study of Lung Cancer
(IASLC) Staging Project. Within the context of this project,
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data on more than 100,000 patients have been collected and
used for proposing a revision of the 6th edition of the tumor,
node, metastasis classification for lung cancer but also for
looking at prognostic factors. The study on prognostic factors
has however been limited by the small number of covariates
being present in the worldwide existing data bases. This is a
further illustration that there are very few factors universally
accepted as important for predicting outcome of the disease.2
Tumor, node, metastasis staging assessment was tradi-
tionally based on conventional imaging but since a decade,
positron emission tomography (PET) with the glucose ana-
logue 2-[18F]-fluoro-2-deoxy-D-glucose (18FDG) has been
successfully introduced in the staging procedures. Indeed,
several meta-analyses have shown that it improves the accu-
racy of the staging assessment.3 This has motivated our group
for performing a systematic review and meta-analysis of the
literature aiming to analyze the possible prognostic value of
FDG-PET for survival.4 The results of this review were
published in January 2008 and suggested that a high stan-
dardized uptake value (SUV) might be a poor prognostic
factor for survival. The estimated hazard ratio (HR) that we
calculated from the combination of 13 studies,5–17 using a
random-effects model, was 2.27 (95% confidence interval
[CI], 1.70–3.02). However, because our search for identify-
ing studies eligible for our review (in June 2006) was
stopped, several further publications on the same topic oc-
curred, some of them focusing on specific disease stages. We
therefore decided that it was worth to update our review.
MATERIALS AND METHODS
For obvious reasons, we followed the same methodol-
ogy as for our previous report, but we summarized it shortly
here after.
We looked for studies dedicated to lung cancer only,
performing 18F-FDG-PET assessment on a dedicated device
before any treatment and assessing the relationship between
pretherapeutic SUV and survival. We only considered full
publications (excluding abstracts) in English, French, or
Dutch in peer-reviewed journals.
We electronically searched for studies on Medline us-
ing keywords specified in our previous report and manually
checked the bibliographies of the already selected studies.
We stopped the search in January 2009.
Twelve readers (11 physicians and 1 statistician) ex-
tracted data from the publications for reporting on the indi-
vidual characteristics and results for survival of the identified
articles as well as data for assessing the methodological
characteristics of the reports—on the basis of a published
scale. We scored both the clinical and the PET reports (22
and 20 items, respectively) and expressed the results in
percentage of the maximal theoretical value that can be
obtained. For details about the items that we considered, we
refer the reader to our primary review on the same topic.4
We descriptively analyzed the scores and looked for
any difference between the new studies compared with the
older ones.
We cautiously looked at overlaps between cohorts of
patients in the different publications. In case of such overlaps,
the most recent publication or the one reporting the most
accurately the survival relationship between SUV and sur-
vival was used. If needed, authors were contacted to confirm
or to reject the assumptions of intersections between patients
included in several analyses.
For assessing the impact of SUV on survival, we
considered, as far as possible, for each study, two groups of
patients: one with low SUV (preferably using the median of
the observed SUV distribution) and one with high SUV. We
thereafter attempted to extract an estimated HR for the
comparison of the two survival distributions using as refer-
ence the group of patients with low SUV and an estimate of
the variance of this estimated HR. Several methods were used
depending on the available information in the individual
publications as in our previously published meta-analysis4:
we looked first, for the univariate HR estimate and 95% CI if
provided by the author; second, for the logrank test result,
number of events, and numbers of patients in each group
allowing to retrieve the HR; third, we read the survival rates
on the survival curves; and finally, we searched for an
adjusted HR (for several baseline factors considered by the
authors).
Selection bias was assessed graphically using funnel
plot.18 Heterogeneity between studies was assessed by using
a 2 test for heterogeneity, and combined HRs were obtained
by the use of fixed-effects models in case of absence of
heterogeneity and of random-effects models otherwise.4 In-
teraction tests were performed using 2 tests.
As far as possible, the median values of SUV uptake
was used for defining the threshold splitting the patients into
two groups. Indeed, the so-called “best cut-off” method has
been shown to be associated with a high probability of false
positive result and to provide a biased, unreliable, and non-
reproducible estimate of the prognostic impact of the tested
covariate.19 We performed sensitivity analyses including and
excluding the studies where only results according to the best
cut-off were available.
The a priori specified objectives of the analysis were to
combine all studies and to look for interactions between
publication time (new studies versus older ones), stage and
histology, whenever possible. As secondary objective, we
planned to assess the possibility of getting aggregated results
for disease free survival.
All reported CIs have a confidence level of 95%, and all
reported p values are two-tailed. We used 5% as threshold for
significance.
RESULTS
Eligible Studies
Thirteen studies, published between 1998 and 2006,
were identified and considered eligible from our previous
search with a total number of 1474 patients included in the
different series.
We selected 14 publications published between 2006
and 2008.20–33 Three of them were considered as ineligible:
one because many patients had treatment before SUV assess-
ment,27 one21 because it was uncertain that SUV assessment
was done before treatment and one because the authors did
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not measure SUV on the primary tumor but considered the
highest SUV value on all the identified lesions.22
Thus, in total, 24 studies were eligible for our review,
13 considered as “older” publications from the first system-
atic review and 11 called the “newer” publications published
after our previous meta-analysis. Some characteristics of the
patients populations considered in these 24 studies are re-
ported in Table 1. The numbers of patients included in the
different studies ranged from 19 to 487. Metastatic patients
are under-represented in the studies; half of them explicitly
mentioning that inclusion of stage IV patients were not
considered. Only one study is dedicated to advanced stages
(from IIIA to IV) and, even in this study, the rate of stage IV
patients is 43%, rate which is still below the rate of stage
IV patients expected in a general population of newly diag-
nosed patients (around 60% in the hospital cancer registry of
Institut Bordet). The proportions of patients with adenocar-
cinoma or with squamous cell histology are also heteroge-
neous from one study to another; one study has been fully
dedicated to patients with pure or mixed bronchioloalveolar
carcinoma. Most of the studies (18/24) used SUV max for
analyzing the relationship between tumor metabolic activity
and survival as reported in Table 1.
All 24 eligible studies were scored according to the
scale, we previously published.4 This score includes two
subscores: one for the clinical part of the study (items related
to the report of the description of the patients population, the
study design, the description of therapeutic characteristics,
and the description of the radiologic assessments) and one for
the PET report (looking at the technical parameters for SUV
assessment and patients selection). Considering the 24 studies
altogether, the median overall score was 56%, ranging from
27% to 68%. Recently published studies did not get signifi-
cantly higher scores than the older publications (medians of
54% versus 57%, P  0.25). The median clinical score was
60% (ranging from 34% to 80%) without detectable differ-
ence between the two series of publications (median of 55%
for the newer ones versus 61% for the older ones, P  0.39).
Finally, the median value of the score describing the charac-
teristics of the PET scan methodology was 51% (from 5% to
65%) with medians of 48% versus 53% for recent versus
older publications, respectively (P  0.78). The clinical,
PET, and total scores are presented in Table 2.
Evaluable Studies
We considered as inevaluable and excluded from fur-
ther analyses three publications. The first one,29 because we
thought that the analysis was potentially biased. Indeed, in
that study including surgically treated patients, all patients
recurring locally were excluded from the analysis because the
TABLE 1. Characteristics of the Patient Populations Included in the 24 Eligible Studies
Study
Year of
Publication
No. of
Patients
Type of
SUV ISS % ADC % SCC Stage % Stage IV
Ahuja et al.5 1998 155 Mean 1997 ? ? I–IV ?
Sugawara et al.6 1999 38 Max 1986 50 32 I–IV 13
Vansteenkiste et al.7 1999 125 Max 1997 25 54 I–IIIB 0
Dhital et al.8 2000 77 Max 1986 23 58 ? ?
Higashi et al.9 2002 57 Mean 1997 67 0 I–III 0
Jeong et al.10 2002 73 Max 1997 41 51 I–IV ?
Downey et al.11 2004 100 Max 1997 67 24 ? ?
Borst et al.a12 2005 51 Max ? 25 33 I–III 0
Cerfolio et al.b13 2005 315 Max 1997 31 51 I–IV 10
Port et al.14 2005 64 ? ? 88 8 ? ?
Sasaki et al.15 2005 162 Max 1997 46 43 I–III ?
Eschmann et al.16 2006 137 Mean 1997? 29 45 IIIA/IIIB 0
Prevost et al.17 2006 120 Mean/max 1997 49 38 I–IV? ?
Raz et al.23 2006 36 ? 1997 0 0 ? ?
de Jong et al.24 2007 66 Max 1997 35 53 I–IIIA 0
Downey et al.25 2007 487 Max 1997 69 21 I–IV 2
Lee et al.26 2007 19 ? 1997 ? ? I–IV 26
Na et al.27 2007 57 Max 1997 33 53 IIIA N2 0
van Baardwijk et al.28 2007 102/46c Max 1997 30 57 I–IIIB 0
Vesselle et al.29 2007 208 Max 1997 38 27 I–IV 19
Zhang et al.30 2007 82 Max 1997 ? 56 I–III 0
Goodgame et al.31 2008 136 Max 1997 52 35 I 0
Hanin et al.32 2008 96 Max 1997 47 48 I/II 0
Hoang et al.33 2008 214 Max 1997 38 30 IIIA/IIIB/IV 43
a Study considered as not fully eligible because of inclusion of 11 patients without histological proof of lung cancer but included in the primary review.4
b Study considered as not fully eligible in the primary review4 because it was unclear that histological proof of lung cancer was obtained for all patients (but first author confirmed
later that it was the case).
c Fifty-six of these 102 patients were included in Ref 7.
SUV, standardized uptake value; ISS, International Staging System; ADC, adenocarcinoma; SCC, squamous cell carcinoma.
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authors considered, in such a situation, that the surgical
treatment was inadequate. However, there might be an asso-
ciation between local recurrence and SUV value with a
potential bias in the assessment of the relationship between
survival and SUV induced by the selection. As the number of
patients excluded from the analysis was not specified, we
preferred to classify this study as inevaluable. The two other
discarded studies were the study by Na et al.27 and by Lee et
al.26 because reported data were insufficient to extract a HR
estimate (in one case SUV was assessed as a continuous
covariate, in the other case, it was only reported that no
relationship between SUV and survival was identified). The
three studies included together 284 patients (9.7% of the total
number of patients registered in the evaluable studies which
is 2922). The corresponding authors of Refs. 27 and 26 were
contacted but did not reply27 or could not provide the re-
quested data.26
Consideration of Overlaps Between Patient
Cohorts
Two publications were reported by Downey et al.11,25
with overlapping accrual periods. The author was contacted
and replied that about 35 patients of 100 from the first study
were likely to be included in the second one. As the overlap
was not total, we reported our results with and without the
first study by Downey et al.
As the cohorts reported by Guo et al.34 and by Higashi
et al.35 in 2000 were fully included in the patients populations
published by Higashi et al.9 in 2002, we even did not consider
as eligible the publications by Guo and Higashi (2000).
van Baardwijk et al.28 reported a pooled analysis of
patients recruited in two different institutions, one cohort
from Leuven and one cohort from Maastricht. We got con-
firmation that the Leuven’s cohort is a subgroup of the
patients population published earlier by Vansteenkiste et al.,7
and we excluded the patients from Leuven from the meta-
analysis as the results from the two institutions were reported
separately in the publication by Van Baardwijk et al.28
Ahuja et al.5 and Hoang et al.33 reported on two patients
cohorts diagnosed during intersecting periods in the same
institution. The corresponding author (N. Patz) warranted that
there was no or minimal overlap between the two cohorts,
and we kept the two studies in our meta-analysis.
Individual Results
Table 3 shows the 21 evaluable studies that were
included in the meta-analysis with the threshold of SUV used
in each series and the method we applied for retrieving an
estimate of the HR between the group with high SUV values
and the group with low SUV values. It also reports on the
individual conclusions regarding the association between
SUV and disease-free survival or overall survival. As it was
already the case in our previous review, the thresholds used
by the authors were heterogeneous, and this heterogeneity is
explained by many factors including: the type of PET ma-
chine, the algorithms for iteration and reconstruction, the type
of correction (weight, lean body mass, etc.), the time elapsed
between FDG injection and emission scan, the type of uptake
use (mean, max, etc.), the patients populations, and the
method for threshold determination (median, the so called
best cut-off method, etc.).
Most of the studies identified high values of SUV as
being of poor prognosis. Only four studies, three relatively
small sized and one dedicated to advanced stages failed to
identify a prognostic impact of SUV.
Table 4 reports the individual HR estimates together
with their CIs at 95%. By convention, a HR higher than 1
means a worse prognosis for patients with high SUV values.
Figure 1 shows the graphical representation of the association
between effect size and study size. In the absence of publi-
cation bias, this plot should look like a funnel, which seems
to be the case for the studies we identified for our review.
Indeed, it is expected that the HRs from individual studies
should converge toward the true HR when sample size is
increasing. Therefore, we should observe a larger spread for
small sample sizes than for larger sample sizes with a sym-
metric pattern. Figure 2 provides a graphical representation of
the point estimates of the HR from the individual studies
together with their CI at the 95% level.
TABLE 2. Methodological Scores for the 24 Eligible Studies
Study
No. of
Patients
Clinical
Score
PET
Score
Total
Score
Ahuja et al.5 155 71 50 61
Sugawara et al.6 38 64 58 61
Vansteenkiste et al.7 125 75 35 56
Dhital et al.8 77 34 33 33
Higashi et al.9 57 50 60 55
Jeong et al.10 73 71 65 68
Downey et al.11 100 52 38 45
Borst et al.a12 51 61 53 57
Cerfolio et al.b13 315 71 60 66
Port et al.14 64 48 5 27
Sasaki et al.15 162 59 53 56
Eschmann et al.16 137 80 48 64
Prevost et al.17 120 61 53 57
Raz et al.23 36 52 25 44
de Jong et al.24 66 73 48 51
Downey et al.25 487 55 5 31
Lee et al.26 19 55 58 56
Na et al.27 57 68 63 66
van Baardwijk et al.28 102/46c 34 53 43
Vesselle et al.29 208 61 60 61
Zhang et al.30 82 52 58 54
Goodgame et al.31 136 52 13 33
Hanin et al.32 96 63 43 56
Hoang et al.33 214 52 48 50
a Study considered as not fully eligible because of inclusion of 11 patients without
histological proof of lung cancer but included in the primary review.4
b Study considered as not fully eligible in the primary review4 because it was
unclear that histological proof of lung cancer was obtained for all patients (but first
author confirmed later that it was the case).
c Fifty-six of these 102 patients were included in Ref 7.
The scores quantify the information available in the studies regarding the method-
ology they used at the clinical level and at the imaging level with 18F-fluoro-2-deoxy-
d-glucose positron emission tomography (FDG-PET).
PET, positron emission tomography.
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Survival Data Aggregation
Considering all together the 21 studies (n  2637), we
detected presence of heterogeneity (2 statistic  36.11, 20
df, P  0.01); this heterogeneity can be reduced by discarding
the publication by Sugawara et al.6 with a P value becoming
0.06. Using a random-effects model, we reached a combined
HR of 2.08, significantly different from 1 with a 95% CI
ranging from 1.69 to 2.56. If we restrict the analysis to the
newer studies, we obtained, with a fixed effects model, a
combined HR of 1.80 (95% CI, 1.50–2.16) and using a
random effects model, a pooled estimate of 2.03 (95% CI,
1.53–2.70).
When dividing the studies, according to their publication
date, we obtained a combined HR of 2.03 (95% CI, 1.53–2.70,
random-effects model) for the newer studies (identified after the
publication of our first review). There was no interaction be-
tween the older and the newer publications (P  0.60).
Excluding the study having included some patients
without histologic proof of lung cancer12 and the first study
by Downey et al.11 with overlapping patients, the combined
HR became 2.11 (95% CI, 1.71–2.59) with presence of
heterogeneity (P  0.01).
Excluding the 7 studies having determined the threshold
for the SUV value using the wrongly called best cut-off method,
the combined HR decreased to 1.97 (95% CI, 1.53–2.52) with a
P value for the test for heterogeneity of 0.02.
We further focused on studies having included only
nonmetastatic patients. Fourteen studies were in this situ-
ation. Heterogeneity was not detectable any more (P 
0.26). Combined HRs for fixed-effects and random-effects
TABLE 4. Individual HR Estimates for the 21 Evaluable
Studies
Author N HR
LB
95% CI
UB
95% CI
Ahuja 155 2.05 1.24 3.37
Sugawara 38 0.56 0.21 1.44
Vansteenkiste 125 2.72 1.50 4.94
Dhital 77 1.30 0.70 2.60
Higashi 57 6.20 1.34 28.75
Jeong 73 4.33 1.80 10.45
Downey 100 2.60 1.02 6.64
Borst 51 3.15 1.59 6.22
Cerfolio 315 2.65 1.63 4.31
Port 64 2.36 0.24 22.88
Sasaki 162 7.66 1.41 41.50
Eschmann 137 1.71 1.00 2.93
Prévost 120 2.36 1.34 4.15
Raz 36 9.90 1.20 79.40
De Jong 66 2.93 1.21 7.09
Downey 487 1.58 1.05 2.40
van Baardwijk 3.40 1.40 8.26
Zhang 82 2.36 1.37 4.06
Goodgame 136 1.89 1.20 2.99
Hanin 96 2.83 1.52 5.26
Hoang 214 1.29 0.94 1.76
HR, hazard ratio; LB, lower bound; UB, upper bound; CI, confidence interval.
TABLE 3. Association Between SUV and DFS/OS: Results of Individual Studies
Author Threshold
Type of
Threshold N
N Low
SUV
N High
SUV
Rate Low
SUV Extraction DFS OS
Ahuja 10.0 Best cut-off 155 118 37 76 Logrank NA Poor
Sugawara 8.7 Median 38 19 19 50 Logrank NA Unconclusive
Vansteenkiste 7.0 Best cut-off 125 31 94 25 Logrank NA Poor
Dhital 10.0 Arbitrary 77 44 33 57 HR NA Unconclusive
Higashi 5.0 Best cut-off 57 41 12 72 Logrank Poor Poor
Jeong 7.0 Best cut-off 73 33 40 45 Logrank NA Poor
Downey 9.0 Median 100 50 50 50 Curves NA Poor
Borst 15.0 Median 51 25 26 49 Logrank NA Poor
Cerfolio 10.0 Best cut-off 315 162 153 51 Logrank NA Poor
Port 2.5 ? 64 35 29 55 Logrank NA Unconclusive
Sasaki 5.0 Best cut-off 162 43 119 27 Curves Poor Poor
Eschmann 12.0 Best cut-off 137 99 38 72 Logrank NA Poor
Prevost 10.0 Literature validation 120 99 21 83 Logrank NA Poor
Raz 2.5 ? 36 19 17 53 HR NA Poor
de Jong 6.4 Median  best cut-off 66 33 33 50 HR NA Poor
Downey 5.3 Median 487 243 244 50 Logrank NA Poor
van Baardwijk 11.0 Best cut-off 46 37 33 80 Logrank NA Poor
Zhang 11.0 Median 82 41 41 50 Logrank Poor Poor
Goodgame 5.5 Median 136 65 71 48 Logrank Poor Poor
Hanin 7.8 Median 97 48 49 49 Logrank Poor Poor
Hoang 11.1 Median 214 106 108 50 Logrank NA Unconclusive
SUV, standardized uptake value; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; NA, not available.
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models were 2.18 (95% CI, 1.83–2.60) and 2.25 (95% CI,
1.84–2.75), respectively. Without considering the studies
with best cut-off thresholds, 10 cohorts are remaining in
the analysis without detectable heterogeneity (P  0.25)
and combined HR of 2.11 (95% CI, 1.72–2.59) and 2.18
(95% CI, 1.72–2.77).
It is noteworthy that only one study was dedicated to
advanced stages with 214 patients and 158 observed events
that failed to detect a HR significantly different from 1. In the
subgroup of studies with unselected series for disease stage,
the combined HRs for a fixed-effects model and a random-
effects model were 1.76 (95% CI, 1.44–2.15) and 1.90 (95%
CI, 1.27–2.84), respectively.
There was, however, no significant interaction accord-
ing to the fact that the authors included or excluded patients
with stage IV disease (P  0.46).
As intended in our plan for analysis, we looked for
subgroups according to histology, but we did not find any
single study reporting separately on patients with adenocar-
cinoma or squamous cell histology and none of them ana-
lyzed the possibility of an interaction between histology and
SUV prognostic impact. Few studies looked at some sub-
groups defined by stage or type of treatment (curative resec-
tion for instance) but we did not find consistent subgroups to
analyze separately.
Figure 3 reports on a graphical way the different com-
bined HRs that we estimated.
Finally, four studies report on disease free survival, but we
believed that these studies were not representative enough of the
complete set of studies to justify the calculation of a combined
HR for these four studies that individually all identify high SUV
value as a poor prognostic factor for disease free survival.
FIGURE 1. Funnel plot. Effect
size: neperian logarithm of the haz-
ard ratio.
FIGURE 2. Individual hazard ratios with their 95% confi-
dence interval. Point estimates of individual hazard ratios
with their 95% confidence interval on a logarithmic scale. By
convention, HR 1 means that patients with a higher stan-
dard uptake value (SUV) on the primary tumor have a worse
prognosis.
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DISCUSSION
We confirmed, with 10 further studies and about 1000
additional patients, the results of our first review concluding that
patients with a tumor demonstrating a higher metabolic activity
as measured by SUV have shorter survival than patients with a
tumor with a lower glucose metabolic rate. There are only little
changes in the point estimates but our narrower CIs give more
reliability to the results, especially when we are focusing on
studies looking at more restricted eligibility criteria. Of course,
all the limitations that we addressed in our previous report and in
our other systematic reviews looking at prognostic factors for
survival in lung cancer are still present. We were not able to
assess the independent prognostic value of SUV, and this ques-
tion remains open with contradictory results in the studies that
we identified: for some of them, the prognostic value is kept
after adjustment for other prognostic features and for some of
them, the SUV is left out of adjusted models (for instance in
Downey et al.25 once pathologic staging is taken into account).
The methodology for assessing SUV and the type of FDG-PET
machine are obviously extremely important as there are various
measurement errors that can occur, and we already insisted on
that aspect (we refer the interested reader to appendixes 1 and 2
of our previous review4). There are currently some researchers
starting to work on standardization of assessment methods (con-
ditions of the examination, calibration of the machines, choice of
reconstruction and attenuation algorithms, etc.) and this stan-
dardization is of course crucial for the conduct of multicentric
studies that are most likely needed to establish the independent
prognostic value of SUV. although it does not solve completely
the issue of reproducibility of results.36
Publication bias is another very important issue, but we
did not detect any strong bias, although we did not perform a
formal test as these tests are known to lack from power.18
Heterogeneity was detected and should be worth to explain.
We identified one study inducing heterogeneity6 but this
study is certainly not only the factor responsible for hetero-
geneity. The P value of the test for heterogeneity increased
but remained significant after exclusion of that study. The
case mix of patients and the measurement of SUV itself are
other factors certainly contributing to the heterogeneity but
with the data available in the publications, we were unable to
define subgroups of publications more homogeneous and this
justifies our use of random-effects models. Our results, how-
ever, suggest that the prognostic impact of SUV might be
stage dependent, and it is indeed possible that once a tumor
has advanced characteristics, the anatomic extent of the
tumor is so important for predicting the prognosis that the
metabolic activity measured by SUV max on the primary
tumor has lower prognostic value. This is why the introduc-
tion of other measures of metabolic activity like the tumor
lesion glycolysis might be very interesting.
Our results do not allow to conclude to an optimal
threshold but only that higher values of SUV imply higher
hazards and some authors do in fact suggest that there are not
two groups of patients but rather that there is a continuous
increase in the hazard as SUV increases.24,37 We also know
that SUV is linked to histology and different behaviors may
apply for patients with adenocarcinoma and for patients with
squamous cell lung cancer. Unfortunately, we were not able
to investigate that question as we had to deal with published
results. However, some authors tried to find a “best” discrimi-
nant threshold but without correcting for multiple analyses,38
and it has been well described in the literature that such
methods may lead to the identification of false positive
prognostic factors.19 As far as we could, we used the median
value of the SUV distribution in each individual study and we
addressed the potential bias by considering, as a separate
subgroup, studies, which used a method with better repro-
ducibility chances. The combined HR decreased, as expected,
but remained significantly different from one and represents
likely a less biased estimate of the true impact of SUV.
Some of the limitations of the review that we performed
could be addressed if we were able to conduct a meta-analysis
based on individual patients data. In that situation, it would be
possible to explore the associations between SUV and other
covariates of interest, mainly stage, and histology and, of
outstanding importance, to assess the independent prognostic
value of SUV. It would be worth also to look, in a per study
stratified analysis, at SUV as a continuous covariate although
this raises, again, the issue of standardization of PET assess-
ment. Therefore, we plan to compare the different PET
algorithms used by the study coordinators to define, if pos-
sible, groups of studies with more homogeneous methodol-
ogy for the measure of the metabolic activity. It would also be
possible to better select the patients by excluding overlapping
information and restricting the analysis to patients with his-
tologic proof of cancer. Finally, updating the survival data
would also be beneficial. After our first review, we contacted
all the corresponding authors for proposing such a meta-
analysis, but despite the interest shown by many of them for
such a project, we did not yet collect a sufficient number of
data bases to conduct an individual patients’ data. The project
will now be endorsed by the IASLC staging project and we
intent, in the following weeks, to contact again authors of the
“older” publications and to get in touch the authors of the
more recent publications on behalf of the IASLC. We believe
that such a cooperation and such an analysis would allow to
obtain new and interesting results and, ultimately, to plan a
prospective prognostic factors study with an a priori calcu-
lated sample size, which would be the last step to provide
definite results about the interest to integrate a measure of the
metabolic activity of the tumor in prognostic models.
FIGURE 3. Combined HRs for survival results ag-
gregation using different subsets of studies. Com-
bined hazard ratios with 95% confidence intervals
obtained from random-effects models.
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